Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.
Company profile
Ticker
KBLB
Exchange
Website
CEO
Kim K. Thompson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Prodigy Textiles Ltd ...
KBLB stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
1 Apr 24
8-K
Unregistered Sales of Equity Securities
1 Apr 24
S-1/A
IPO registration (amended)
22 Nov 23
424B3
Prospectus supplement
16 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
424B3
Prospectus supplement
11 Sep 23
EFFECT
Notice of effectiveness
8 Sep 23
S-1/A
IPO registration (amended)
1 Sep 23
POS AM
Prospectus update (post-effective amendment)
1 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
Latest ownership filings
4
Jonathan Richard Rice
17 Feb 23
4
Kimberly Kraig Thompson
21 Jul 22
4
Kimberly Kraig Thompson
19 Jul 22
4
Kimberly Kraig Thompson
15 Jul 22
4
Kimberly Kraig Thompson
13 Jul 22
4
Kimberly Kraig Thompson
11 Jul 22
4
Kimberly Kraig Thompson
7 Jul 22
4
Kimberly Kraig Thompson
1 Jul 22
4
Kimberly Kraig Thompson
29 Jun 22
4
Kimberly Kraig Thompson
24 Jun 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.89 mm | 2.89 mm | 2.89 mm | 2.89 mm | 2.89 mm | 2.89 mm |
Cash burn (monthly) | (no burn) | 80.68 k | 183.09 k | 221.00 k | 82.91 k | 113.20 k |
Cash used (since last report) | n/a | 538.59 k | 1.22 mm | 1.48 mm | 553.45 k | 755.66 k |
Cash remaining | n/a | 2.36 mm | 1.67 mm | 1.42 mm | 2.34 mm | 2.14 mm |
Runway (months of cash) | n/a | 29.2 | 9.1 | 6.4 | 28.2 | 18.9 |
Institutional ownership, Q4 2022
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 3.10 mm |
Total shares | 100.00 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tower Bridge Advisors | 100.00 k | $3.10 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Feb 23 | Jonathan Richard Rice | Class A Common Stock Option Class A Common Stock | Acquire X | No | No | 0 | 2,434,211 | 0.00 | 500,000 |
Press releases
Kraig Biocraft Laboratories Announces Successful Launch of Spring Production Trials in Southeast Asia for Spider Silk
15 Apr 24
Kraig Biocraft Laboratories Signs Landmark Agreement in Vietnam's Silk Production Capital
8 Apr 24
Kraig Biocraft Laboratories Shares Industry Update on Recombinant Spider Silk from Waste Plastics
28 Mar 24
Kraig Biocraft Laboratories Senior Management travels to Vietnam for Launch of Spring Trials
12 Mar 24
Kraig Biocraft Laboratories Establishes Homozygosity and Confirms BAM 1 Hybrid Optimized Ahead of Spring Production Trials
27 Feb 24